Tim Knotnerus

Tim is CEO and member of the Board of Directors of Agomab. Together with the team, he has raised around $100M from top US and EU investors since joining Agomab in 2019. Prior to Agomab, Tim held the position of VP Corporate Development at AM-Pharma where he and the team executed a Phase IIb trial in patients with sepsis-associated acute kidney injury, secured an option-to-buy deal with Pfizer and raised significant private financing rounds. Prior to that, Tim was a Senior Associate at Aescap Venture, a VC fund investing in European medical companies. Tim is a Henri Termeer Fellow and holds an executive MBA from IMD, where he was named Valedictorian. He earned a Science and Innovation Masters and a Drug Innovation Masters from Utrecht University.